Lipodystrophy Connect Patient Registry

Lipodystrophy Clinical Trial

Official title:

Lipodystrophy Connect Patient Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02577952
• Other study ID #: Pro00009092
• Status: Completed
• Start date: January 2014
• Est. completion date: November 8, 2018

Study information

• Verified date: April 2019
• Source: PatientCrossroads
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.

Description:

Lipodystrophy is a heterogeneous group of rare and inherited syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue. People living with lipodystrophy lack the fat tissue required for normal metabolic function. To enhance knowledge of the underlying biology of these conditions and to institute effective clinical treatments, the Lipodystrophy community has developed a mechanism for individuals with any of the Lipodystrophy conditions to enroll in a Lipodystrophy registry called Lipodystrophy Connect. The objective of such a registry is to create a platform that connects all of the Lipodystrophy community, including persons with Lipodystrophy, family members, healthcare providers, researchers, drug companies, advocacy groups, federal research organizations, and regulators. A patient registry will provide the foundation for a resource to meet the current and future needs of the Lipodystrophy community as well as accelerate the rate of research and development of therapies that improve the quality of life of those with Lipodystrophy. Lipodystrophy Connect is an online survey tool that collects basic demographic information and health information from people with any rare form of Lipodystrophy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 257
• Est. completion date: November 8, 2018
• Est. primary completion date: November 8, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Adults, > 18 years of age, with a diagnosis or suspected diagnosis of lipodystrophy, who are willing and able to provide informed consent, or for whom a legally authorized representative gives permission on behalf of the person to participate.

• Minors (less than 18 years of age) with a diagnosis of lipodystrophy with a parent(s) or legally authorized representative who provides informed consent to participate and enter registry information on behalf of the minor. Note: Minors who are 7-17 years of age will be asked to provide assent to participate.

• Adults > 18 years of age, without lipodystrophy, who are willing and able to provide informed consent and are family members of patients diagnosed with familial partial lipodystrophy (FPL) or congenital generalized lipodystrophy (CGL) and want to provide information about themselves.

Exclusion Criteria:

• A person who does not have a suspected or confirmed diagnosis of Lipodystrophy.

• A person who has a known diagnosis of HIV-associated Lipodystrophy.

Related Conditions & MeSH terms

• Lipodystrophy

Locations

Country	Name	City	State
United States	PatientCrossroads	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
PatientCrossroads

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Descriptive epidemiology of congenital and acquired lipodystrophy.	Assessed from multiple questions regarding the natural history of patients with congenital or acquired lipodystrophy, with an emphasis on co-morbidities, history of medical evaluation or admission, and use of medications/alternative therapies.	Participants are requested to update their questionnaires every 12 months for 5 years.
Secondary	Data on disease subtype	Multiple questions about the patient's diagnostic process including reported diagnosis and subtype, time to diagnosis, method of diagnosis, age at diagnosis, presenting symptoms and specialty of diagnosing clinician.	Participants are requested to update their questionnaires every 12 months for 5 years.
Secondary	Change in congenital and acquired lipodystrophy clinical features	Assessed from multiple questions regarding the common physical features hallmark to congenital and acquired lipodystrophy.	Participants are requested to update their questionnaires every 12 months for 5 years.
Secondary	Change in patient self-report Quality of Life	Assessed from self-report quality-of-life (QoL) questions about the patient's overall health, everyday living, recent impact, personal impact, available resources, diet and lifestyle history.	Participants are requested to update their questionnaires every 12 months for 5 years.
Secondary	Data on family and reproductive history	Multiple questions regarding whether biological family members have been diagnosed with lipodystrophy or report lipodystrophy symptoms, and personal reproductive history.	Participants are requested to update their questionnaires every 12 months for 5 years.

External Links

•   Lipodystrophy Connect